Literature DB >> 7705419

CD40 ligand is functionally expressed on human eosinophils.

J F Gauchat1, S Henchoz, D Fattah, G Mazzei, J P Aubry, T Jomotte, L Dash, K Page, R Solari, D Aldebert.   

Abstract

CD40 ligand (CD40L), a surface molecule which can be expressed by T cells, mast cells and basophils, has been shown to be involved in the control of B cell proliferation, immunoglobulin class switching as well as in the activation of monocytes and T cells. We demonstrate that CD40L can also be expressed constitutively by eosinophils from an hypereosinophilic patient or, upon activation, by the eosinophilic cell line EOL-3 and normal blood eosinophils. Eosinophils were able to induce, in conjunction with IL-4, CD40L-dependent B cell proliferation in vitro. These results suggest that CD40L could play a role in the inflammatory processes during which eosinophil infiltration and activation are observed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705419     DOI: 10.1002/eji.1830250335

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

1.  High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.

Authors:  M Uguccioni; C R Mackay; B Ochensberger; P Loetscher; S Rhis; G J LaRosa; P Rao; P D Ponath; M Baggiolini; C A Dahinden
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  CD40 restrains in vivo growth of Toxoplasma gondii independently of gamma interferon.

Authors:  Carlos S Subauste; Matthew Wessendarp
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

3.  Activation-induced cytidine deaminase expression and activity in the absence of germinal centers: insights into hyper-IgM syndrome.

Authors:  Masayuki Kuraoka; Dongmei Liao; Kaiyong Yang; Sallie D Allgood; Marc C Levesque; Garnett Kelsoe; Yoshihiro Ueda
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 4.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling.

Authors:  S Toyabe; A Watanabe; W Harada; T Karasawa; M Uchiyama
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

6.  Abnormal CD40 ligand (CD154) expression in human immunodeficiency virus-infected children.

Authors:  M R O'Gorman; B DuChateau; M Paniagua; J Hunt; N Bensen; R Yogev
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

7.  CD40 expression by human peripheral blood eosinophils.

Authors:  Y Ohkawara; K G Lim; Z Xing; M Glibetic; K Nakano; J Dolovich; K Croitoru; P F Weller; M Jordana
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

8.  A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line.

Authors:  Mario I Vega; Leopoldo Santos-Argumedo; Sara Huerta-Yepez; Rosendo Luría-Perez; Vianney Ortiz-Navarrete; Armado Isibasi; Cesar R González-Bonilla
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

9.  Premature labor: a state of platelet activation?

Authors:  Offer Erez; Roberto Romero; Debra Hoppensteadt; Jawed Fareed; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Nandor Gabor Than; Edi Vaisbuch; Chong Jai Kim; Jimmy Espinoza; Pooja Mittal; Neil Hamill; Chia-Ling Nhan-Chang; Moshe Mazor; Sonia Hassan
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

10.  Hypereosinophilia presenting as eosinophilic vasculitis and multiple peripheral artery occlusions without organ involvement.

Authors:  Sung-Hwan Kim; Tae-Bum Kim; Young-Sun Yun; Jung-Im Shin; Il-Young Oh; Jung-Ju Sir; Kyung-Mook Kim; Hye-Kyung Park; Hye-Ryun Kang; Yoon-Seok Chang; Yoon-Keun Kim; Sang-Heon Cho; Yeong-Wook Song; Dong-Chul Choi; Kyung-Up Min; You-Young Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.